why choose us

First received: June 21, 2024

Clinical Trial: A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Healthy

Study Type: INTERVENTIONAL


Official Title: A Bioequivalence Study of Subcutaneous Injections of Citrate-Free Mirikizumab Solution Using a 1-mL Autoinjector and an Investigational 2-mL Autoinjector in Healthy Participants

Brief Summary: The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector.Screening is required within 35 days prior to enrollment.For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening.

Read more